

1 ***Inferring Multi-Organ Genetic Causal Connections using Imaging and Clinical Data***  
2 ***through Mendelian Randomization***

3

4 **Running title: MR atlas for multi-organ images**

5

6 Juan Shu<sup>1</sup>, Rong Zheng<sup>2</sup>, Julio Chirinos<sup>3,4</sup>, Carlos Copana<sup>1</sup>, Bingxuan Li<sup>5</sup>, Zirui Fan<sup>6</sup>,  
7 Xiaochen Yang<sup>1</sup>, Yilin Yang<sup>7</sup>, Xiyao Wang<sup>8</sup>, Yujue Li<sup>1</sup>, Bowei Xi<sup>1</sup>, Tengfei Li<sup>9,10</sup>, Hongtu Zhu<sup>11-  
8 14\*</sup>, and Bingxin Zhao<sup>1,6,15-19\*#</sup>

9

10 <sup>1</sup>Department of Statistics, Purdue University, West Lafayette, IN 47907, USA.

11 <sup>2</sup>Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi  
12 030001, China.

13 <sup>3</sup>Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA  
14 19104, USA.

15 <sup>4</sup>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

16 <sup>5</sup>UCLA Samueli School of Engineering, Los Angeles, CA 90095, USA.

17 <sup>6</sup>Department of Statistics and Data Science, University of Pennsylvania, Philadelphia, PA 19104,  
18 USA.

19 <sup>7</sup>Department of Computer and Information Science and Electrical and Systems Engineering,  
20 School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA 19104,  
21 USA.

22 <sup>8</sup>Department of Computer Science, Purdue University, West Lafayette, IN 47907, USA.

23 <sup>9</sup>Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

24 <sup>10</sup>Biomedical Research Imaging Center, School of Medicine, University of North Carolina at Chapel  
25 Hill, Chapel Hill, NC 27599, USA.

26 <sup>11</sup>Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599,  
27 USA.

28 <sup>12</sup>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

29 <sup>13</sup>Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC  
30 27599, USA.

31 <sup>14</sup>Department of Statistics and Operations Research, University of North Carolina at Chapel Hill,  
32 Chapel Hill, NC 27599, USA.

1 <sup>15</sup>Applied Mathematics and Computational Science Graduate Group, University of Pennsylvania,  
2 Philadelphia, PA 19104, USA.

3 <sup>16</sup>Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine,  
4 University of Pennsylvania, Philadelphia, PA 19104, USA.

5 <sup>17</sup>Penn Institute for Biomedical Informatics, Perelman School of Medicine, University of  
6 Pennsylvania, Philadelphia, PA 19104, USA.

7 <sup>18</sup>Population Aging Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

8 <sup>19</sup>Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia,  
9 PA 19104, USA.

10

11 *\*Corresponding authors:*

12 Hongtu Zhu ([htzhu@email.unc.edu](mailto:htzhu@email.unc.edu)) and Bingxin Zhao ([bxzhao@upenn.edu](mailto:bxzhao@upenn.edu))

13

14 *#Lead contact:*

15 Bingxin Zhao

16 413 Academic Research Building

17 265 South 37th Street, Philadelphia, PA 19104.

18 E-mail: [bxzhao@upenn.edu](mailto:bxzhao@upenn.edu) Phone: (215) 898-8222

1 **Abstract**

2 Understanding the complex causal relationships among major clinical outcomes and the  
3 causal interplay among multiple organs remains a significant challenge. By using imaging  
4 phenotypes, we can characterize the functional and structural architecture of major  
5 human organs. Mendelian randomization (MR) provides a valuable framework for  
6 inferring causality by leveraging genetic variants as instrumental variables. In this study,  
7 we conducted a systematic multi-organ MR analysis involving 402 imaging traits and 372  
8 clinical outcomes. Our analysis revealed 184 genetic causal links for 58 diseases and 56  
9 imaging traits across various organs, tissues, and systems, including the brain, heart, liver,  
10 kidney, lung, pancreas, spleen, adipose tissue, and skeletal system. We identified intra-  
11 organ causal connections, such as the bidirectional genetic links between Alzheimer's  
12 disease and brain function, as well as inter-organ causal effects, such as the impact of  
13 heart diseases on brain health. Metabolic disorders, such as diabetes, exhibited causal  
14 effects across multiple organs. These findings shed light on the genetic causal links  
15 spanning multiple organs, providing insights into the intricate relationships between  
16 organ functions and clinical outcomes.

17

18 **Keywords:** Abdominal MRI; Brain MRI; Cardiovascular MRI; Clinical outcomes; FinnGen;  
19 GWAS; Mendelian randomization; Skeleton DXA; UK Biobank.

1 Medical imaging techniques such as magnetic resonance imaging (MRI) provide important  
2 information about the structure and function of many human organs, such as the brain,  
3 heart, liver, and kidney. Their derived imaging traits have found widespread use in both  
4 clinical research and practical applications. For example, structural and functional imaging  
5 traits extracted from brain MRIs have consistently revealed abnormalities associated with  
6 Alzheimer's disease, particularly within the hippocampal region<sup>1</sup>. Cardiovascular MRI  
7 (CMR) provides quantitative data regarding ventricular function, cardiovascular structure,  
8 and myocardial perfusion, all of which are intricately linked to cardiovascular diseases<sup>2</sup>.  
9 Furthermore, skeletal dual-energy X-ray absorptiometry (DXA) aids in identifying novel  
10 genetic variants that influence the human skeletal structure, thereby revealing significant  
11 evolutionary trends in human anatomical changes leading to pathogenesis<sup>3</sup>. Several large-  
12 scale organ imaging datasets (on the scale of over 10,000 participants) have recently been  
13 made publicly available, revealing details about human organ structure and function<sup>4-8</sup>. A  
14 large number of complex traits and clinical outcomes have been found to associate with  
15 organ imaging traits in these population-based studies<sup>9,10</sup>.

16  
17 Despite these advances, inherent limitations in observational data pose challenges in  
18 definitively establishing causal relationships between imaging traits and clinical outcomes,  
19 as well as in gaining a comprehensive understanding of the causal interplay across various  
20 organs<sup>11</sup>. Mendelian randomization (MR) uses genetic variants as instrumental variables  
21 to infer causality from observational data<sup>12,13</sup>. Operating under certain assumptions  
22 regarding genetic, exposure, and outcome variables, MR is an epidemiological tool to  
23 uncover causal relationships between exposure and outcome variables, while controlling  
24 for confounding factors. Both family and population-based studies have demonstrated  
25 that numerous imaging traits and complex diseases are profoundly influenced by genetics.  
26 Hundreds of associated genetic loci have been pinpointed in large-scale genome-wide  
27 association studies (GWAS)<sup>3,8,14-28</sup>. Using these GWAS summary-level data (summary  
28 statistics), MR methods can unveil causal relationships between imaging measurements  
29 and clinical outcomes. Numerous recent MR studies have explored the genetic causality  
30 of imaging traits<sup>11,29-34</sup>. However, a common limitation of these MR studies is their focus  
31 on a single organ (or imaging modality) and/or a single disease, or diseases in a specific  
32 domain, such as brain imaging and psychiatric disorders<sup>29</sup>. It is crucial to note, however,

1 that many diseases act as the causes and/or consequences of functional and structural  
2 changes in various organs of the human body<sup>35,36</sup>. Cross-organ analysis can elucidate the  
3 complexity of human physiology and holds great potential to improve our understanding  
4 of a multitude of diseases, ultimately enhancing our strategies for their diagnosis,  
5 treatment and prevention. Consequently, it is essential to conduct MR analysis from a  
6 multi-organ perspective to comprehend the clinical implications of imaging traits amidst  
7 the complex interrelationships of organ systems.

8

9 In this paper, we carried out a systematic two-sample MR analysis to explore the causal  
10 relationships between multi-organ imaging and clinical endpoints. We consolidated  
11 GWAS summary statistics from 402 multi-organ imaging traits (with an average sample  
12 size  $n \approx 35,000$ ) from the UK Biobank (UKB)<sup>37</sup> study along with 372 clinical outcomes (304  
13 with more than 10,000 cases and 68 more with at least 5000 cases) sourced from the  
14 FinnGen project<sup>27</sup> (**Tables S1-S2**). Our focus was on three major brain MRI modalities: 1)  
15 101 regional brain volumes<sup>21</sup> from structural MRI (sMRI); 2) 110 diffusion tensor imaging  
16 (DTI) parameters<sup>23</sup> from diffusion MRI (dMRI); and 3) 90 functional activity (amplitude<sup>38</sup>)  
17 and connectivity traits from functional MRI (fMRI)<sup>25</sup>. Furthermore, we incorporated 82  
18 CMR traits extracted from short-axis, long-axis, and aortic cine cardiac MRI<sup>39,40</sup>. We also  
19 considered 11 abdominal MRI traits, measuring volume, fat, or iron content in seven  
20 organs and tissues<sup>8</sup>, and eight DXA imaging traits that gauged the lengths of all long bones  
21 and the width of the hip and shoulder<sup>3</sup>. We applied 8 MR methods<sup>41-49</sup> to investigate  
22 bidirectional genetic causal links. The study design is presented in **Figure 1A**, while **Figure**  
23 **1B** offers a high-level summary of our key findings. Additional details on these multi-organ  
24 imaging traits are provided in the **Methods** section.

25

## 26 **RESULTS**

### 27 **Genetic causality between brain imaging and multi-organ diseases**

28 We explored the causal relationship between brain imaging traits and multi-organ  
29 diseases. At a false discovery rate (FDR) 5% level ( $P < 1.31 \times 10^{-4}$ , adjusting for multiple  
30 testing for both directions), MR identified 33 significant genetic causal effects of 6  
31 diseases (within 4 major categories) on 6 brain imaging traits. These categories included  
32 diseases of the nervous system, diseases of the circulatory system, diseases marked as

1 autoimmune origin, and diseases of the digestive system. Among these 33 significant  
2 findings, 14 were associated with hypertension (9 with hypertension and 5 with essential  
3 hypertension), 12 with Alzheimer's disease and dementia, 5 with autoimmune diseases,  
4 1 with allergic asthma, and 1 with atrial fibrillation (**Table S3**).

5  
6 Our results revealed that neurodegenerative conditions, including dementia and  
7 Alzheimer's disease, could potentially impair functional activity across various networks.  
8 Specifically, dementia and Alzheimer's disease were consistently found to compromise  
9 the integrity of the default mode ( $\beta < -0.09$ ,  $P < 2.19 \times 10^{-5}$ , >6/8 MR methods significant),  
10 dorsal-attention ( $\beta < -0.05$ ,  $P < 2.24 \times 10^{-5}$ , >5/8 MR methods significant), and  
11 frontoparietal networks ( $\beta < -0.03$ ,  $P < 4.53 \times 10^{-5}$ , >5/8 MR methods significant) (**Fig. 2A**).  
12 In addition to degenerative neurological diseases, we consistently observed causal effects  
13 of hypertension on regional brain volume, fMRI traits, and DTI parameters. For example,  
14 hypertension had negative causal effects on grey matter volume ( $\beta < -0.03$ ,  $P < 1.30 \times 10^{-$   
15  $10$ , 5/8 MR methods significant). Similarly, a potential negative effect of hypertension was  
16 observed on the fractional anisotropy (FA) of the body of the corpus callosum tract (BCC,  
17  $\beta < -0.07$ ,  $P < 1.12 \times 10^{-6}$ , 6/8 MR methods significant) and the genu of the corpus callosum  
18 (GCC,  $\beta < -0.01$ ,  $P < 2.29 \times 10^{-5}$ , 6/8 MR methods significant). Conversely, positive effects  
19 were found on other DTI parameters, such as axial diffusivity (AD), mean diffusivity (MD)  
20 and radial diffusivity (RD) of superior corona radiata (SCR), RD of BCC, as well as RD of  
21 GCC ( $\beta > 0.01$ ,  $P < 4.30 \times 10^{-5}$ , 6/8 MR methods significant). It makes sense as lower MD  
22 and higher FA values typically indicating better white matter health<sup>50</sup>. In addition, we  
23 observed that hypertension was causally related to decreased functional connectivity of  
24 the orbito-affective network ( $\beta > -0.05$ ,  $P < 1.16 \times 10^{-5}$ , 6/8 MR methods significant) (**Fig.**  
25 **2B**). Autoimmune diseases were mostly found to affect DTI parameters, such as the AD  
26 and MD of SCR ( $\beta < -0.04$ ,  $P < 9.43 \times 10^{-5}$ , >5/8 MR methods significant) (**Fig. 2C**).

27  
28 Brain and other organ-related diseases may also be affected by structural or functional  
29 changes in the brain. To investigate this, we used brain imaging traits as exposure  
30 variables and clinical endpoints as the outcome variables. At an FDR 5% level ( $P < 1.31 \times 10^{-$   
31  $4$ ), we identified 12 significant relationships between 5 brain imaging traits and 3 types of  
32 clinical endpoints (**Table S3**). Most of the significant imaging-disease pairs were related

1 to DTI parameters and the majority of the significant findings pertained to brain diseases  
2 (11/12). For example, we found that the RD of BCC and GCC was causally related to  
3 dementia ( $\beta < -0.31$ ,  $P < 1.47 \times 10^{-5}$ ,  $>5/8$  MR methods significant), and the FA of SCR was  
4 associated with an increased risk of Alzheimer's disease ( $\beta > 0.33$ ,  $P < 6.24 \times 10^{-5}$ ,  $7/8$  MR  
5 methods significant) (**Fig. 2D**).

6

### 7 **Causal genetic relationships between CMR traits and clinical outcomes**

8 We assessed the potential causal effects from clinical endpoints to CMR measures of  
9 heart structure and function. We identified 137 significant results at an FDR 5% level ( $P <$   
10  $6.95 \times 10^{-4}$ ), including 44 unique CMR traits of the ascending aorta (AAo), descending aorta  
11 (Dao), left atrium (LA), right ventricle (RV), and left ventricle (LV). These significant causal  
12 effects were identified in 20 unique clinical endpoints of 5 categories: diseases of the  
13 circulatory system (10/20), endocrine, nutritional and metabolic diseases (6/20), mental  
14 and behavioral disorders (2/20), diseases of eye and adnexa (1/20), as well as neoplasms  
15 (ICD2 & ICD-O-3, 1/20). Among the 137 significant findings, 117 were associated with  
16 heart-related diseases (114 diseases of the circulatory system and 3 cardiac arrhythmias),  
17 15 with endocrine, nutritional and metabolic diseases, and 3 with mental and behavioral  
18 disorders (**Table S4**).

19

20 Causal effects of hypertension were widely observed on many LV traits, such as global  
21 and regional<sup>51</sup> myocardial-wall thickness (segments 1-16,  $\beta > 0.07$ ,  $P < 6.44 \times 10^{-5}$ ,  $7/8$  MR  
22 methods significant) and radial strain traits (segments 7-9 and 12-15,  $\beta > 0.06$ ,  $P <$   
23  $8.14 \times 10^{-5}$ ,  $7/8$  MR methods significant). In addition to LV traits, hypertension also  
24 affected multiple other CMR traits. For example, it had negative causal impacts on Aao  
25 and Dao distensibility<sup>52-54</sup> ( $\beta < -0.10$ ,  $P < 2.11 \times 10^{-5}$ ,  $7/8$  MR methods significant), as well  
26 as positive effects on AAo and Dao minimum/maximum areas (AAo<sub>max</sub> and AAo<sub>min</sub> areas,  
27  $\beta > 0.10$ ,  $P < 3.32 \times 10^{-6}$ ,  $7/8$  MR methods significant). The causal effects were also  
28 observed in several LA traits, such as negative effects on the left atrium ejection fraction  
29 ( $\beta < -0.07$ ,  $P < 4.45 \times 10^{-4}$ ,  $7/8$  MR methods significant) as well as positive effects on left  
30 atrium minimum/maximum volumes (LA<sub>min</sub> and LA<sub>max</sub> volumes,  $\beta > 0.06$ ,  $P < 4.72 \times 10^{-4}$ ,  
31  $6/8$  MR methods significant). Similar to hypertension, we found that cardiovascular  
32 diseases and hypertensive diseases had causal effects on various LV traits, such as

1 regional myocardial-wall thickness, left ventricular myocardial mass, and regional radial  
2 strain. We further identified heart-related disorders that contributed to alterations in  
3 heart structure and function. Conditions such as atrial fibrillation and flutter, heart failure,  
4 and cardiac arrhythmias were primarily linked to LA traits, including negative effects on  
5 the left atrium ejection fraction ( $\beta < -0.07$ ,  $P < 1.35 \times 10^{-5}$ , 7/8 MR methods significant) and  
6 positive effects on LA<sub>min</sub> and LA<sub>max</sub> volumes ( $\beta > 0.07$ ,  $P < 1.08 \times 10^{-6}$ , 7/8 MR methods  
7 significant) (**Fig. 3A**).

8

9 We also observed causal effects of other diseases, such as endocrine, nutritional and  
10 metabolic disorders, on heart structure and function. For example, diabetes was observed  
11 to have negative effects on regional longitudinal strain (segment 2,  $|\beta| > 0.03$ ,  $P < 1.68 \times 10^{-4}$ ,  
12 5/8 MR methods significant) and positive effects on right ventricular ejection fraction  
13 ( $\beta > 0.04$ ,  $P < 1.73 \times 10^{-4}$ , 5/8 MR methods significant). Additionally, type 2 diabetes led to  
14 a lower level of AAO<sub>max</sub> and AAO<sub>min</sub> areas ( $\beta < -0.04$ ,  $P < 3.53 \times 10^{-4}$ , 5/8 MR methods  
15 significant) and larger global and regional myocardial-wall thickness (segments 5-6 and  
16 10-12,  $\beta > 0.03$ ,  $P < 5.35 \times 10^{-4}$ , 5/8 MR methods significant). Pure hypercholesterolemia  
17 and other metabolic disorders were causally linked to an enlarged left atrium stroke  
18 volume ( $\beta > 0.05$ ,  $P < 3.31 \times 10^{-4}$ , 5/8 MR methods significant). Moreover, hypothyroidism  
19 negatively affected regional radial strain (segment 12,  $\beta < -0.05$ ,  $P < 3.31 \times 10^{-4}$ , 5/8 MR  
20 methods significant) (**Fig. 3B**). It is also noteworthy that we found evidence suggestive of  
21 causality for brain disorders on heart phenotypes, such as a potential causal effect of  
22 dementia on right ventricular end-diastolic volume ( $\beta > 0.03$ ,  $P < 2.42 \times 10^{-4}$ , 5/8 MR  
23 methods significant), as well as mood disorders on regional myocardial-wall thickness  
24 (segments 8 and 12,  $\beta < -0.12$ ,  $P < 4.81 \times 10^{-4}$ , 5/8 MR methods significant) (**Fig. 3C**).

25

26 Structural and functional abnormalities within the heart may also increase the risk of  
27 multi-organ diseases, considering the role of the heart in pumping blood to all other  
28 organs<sup>55</sup>. We examined this direction by treating CMR traits as exposure variables and  
29 clinical endpoints as the outcomes. At an FDR 5% level ( $P < 6.95 \times 10^{-4}$ ), we identified 20  
30 significant causal pairs, with most related to heart-related diseases and a small portion to  
31 diseases of the nervous system. Some of these examples correspond to well-known  
32 relationships. For example, larger left ventricular ejection fraction was consistently found



1 to reduce the risk of heart failure ( $\beta < -0.30$ ,  $P < 2.38 \times 10^{-4}$ , 5/8 MR methods significant).  
2 **(Fig. 3D)**. We also found that CMR traits, such as regional myocardial-wall thickness  
3 (segment 5), had causal effects on Alzheimer's disease ( $\beta < -0.60$ ,  $P < 4.85 \times 10^{-4}$ , 5/8 MR  
4 methods significant) **(Fig. 3E)**.

5

### 6 **Causal genetic links between abdominal imaging traits and clinical outcomes**

7 We first examined the causal effects of multi-organ diseases on abdominal imaging traits,  
8 including the volume or iron content of organs like the spleen, kidney, liver, lung, and  
9 pancreas<sup>8</sup>. At an FDR 5% level ( $P < 1.40 \times 10^{-3}$ ), we identified 62 significant causal  
10 relationships between multi-organ diseases and abdominal imaging traits, after excluding  
11 straightforward associations such as the link between obesity and both adipose tissue  
12 volume and abdominal organ fat content. Notably, liver imaging traits constituted the  
13 majority of these findings (34/62). Brain disorders were the most prevalent among the  
14 significant relationships identified (23/62, mental and behavioral disorders (14) and  
15 diseases of the nervous system (9)), followed by endocrine, nutritional and metabolic  
16 diseases (18/62) **(Table S5)**. These findings aligned with ongoing research on the complex  
17 interplay between the brain and abdominal organs, such as the brain-gut connection<sup>56-58</sup>,  
18 brain-kidney connection<sup>59,60</sup>, and brain-liver connection<sup>61</sup>. Specifically, Alzheimer's  
19 disease and dementia were linked to a reduction in liver volume and percent of liver fat  
20 ( $|\beta| > 0.02$ ,  $P < 1.28 \times 10^{-4}$ , 6/8 MR methods significant). Sleep apnea was observed to  
21 positively influence the liver volume and the volume of abdominal subcutaneous adipose  
22 tissue ( $\beta > 0.19$ ,  $P < 9.61 \times 10^{-4}$ , 6/8 MR methods significant). Furthermore, alcohol use  
23 disorder was associated with an increase in percent liver fat ( $\beta > 0.13$ ,  $P < 2.09 \times 10^{-5}$ , 6/8  
24 MR methods significant). In addition to the brain, we found that diabetes was causally  
25 related to a higher percent of liver fat ( $\beta > 0.04$ ,  $P < 2.75 \times 10^{-5}$ , 5/8 MR methods significant)  
26 and increased pancreas fat ( $\beta > 0.5$ ,  $P < 9.14 \times 10^{-5}$ , 5/8 MR methods significant).  
27 Furthermore, we found some autoimmune, rheumatic and infectious diseases were  
28 causally associated with lower levels of liver iron content ( $\beta < -0.04$ ,  $P < 4.47 \times 10^{-4}$ , >6/8  
29 MR methods significant) and larger spleen volume ( $\beta > 0.06$ ,  $P < 4.47 \times 10^{-4}$ , 6/8 MR  
30 methods significant) **(Figs. 4A-C)**.

31

1 Next, we evaluated the opposite direction with abdominal imaging traits as exposure  
2 variables and multi-organ diseases as outcomes. At an FDR 5% level ( $P < 1.40 \times 10^{-3}$ ), we  
3 identified 44 significant pairs, with heart-related diseases occupying 15 among them,  
4 followed by endocrine, nutritional metabolic disorders (10/44), disease of the respiratory  
5 system (4/44), blood and blood-forming (4/44), musculoskeletal and connective (4/44),  
6 and digestive system (4/44). The liver imaging traits were again the most frequent (35/44).  
7 For example, a higher percent of liver fat had causal effects on multiple heart-related  
8 diseases, such as angina pectoris, coronary angioplasty, coronary atherosclerosis,  
9 ischemic heart disease (wide definition), myocardial infarction (strict), as well as heart  
10 failure and coronary heart disease ( $\beta > 0.13$ ,  $P < 1.40 \times 10^{-3}$ , 5/8 MR methods significant).  
11 Further, an enlarged spleen volume was linked to an increased risk of cardiovascular  
12 diseases, such as diseases of arteries, arterioles and capillaries ( $\beta > 0.25$ ,  $P < 1.12 \times 10^{-3}$ ,  
13 5/8 MR methods significant). Beyond cardiovascular impacts, increased liver iron content  
14 significantly elevated the risk of anemias, particularly iron deficiency anemia ( $\beta > 0.19$ ,  $P$   
15  $< 9.80 \times 10^{-4}$ , 5/8 MR methods significant). A causal relationship was observed between  
16 higher percent of liver fat and liver diseases ( $\beta > 0.13$ ,  $P < 1.40 \times 10^{-3}$ , 8/8 MR methods  
17 significant), increased visceral adipose tissue volume and hernia of abdominal wall ( $\beta >$   
18  $0.72$ ,  $P < 1.40 \times 10^{-3}$ , 6/8 MR methods significant), as well as spleen volume and  
19 noninfective enteritis and colitis ( $\beta > 0.13$ ,  $P < 9.66 \times 10^{-4}$ , 5/8 MR methods significant).  
20 Moreover, visceral adipose tissue volume led to an increased risk of asthma and chronic  
21 lower respiratory diseases ( $\beta > 0.30$ ,  $P < 1.10 \times 10^{-3}$ , 5/8 MR methods significant) (**Fig. 4D**).

22

### 23 **Causal genetic links between skeleton DXA traits and clinical outcomes**

24 The skeletal system serves as the foundational support for the human body, and as such,  
25 skeletal abnormalities could potentially contribute to the risk of multi-organ diseases. We  
26 identified 8 causal pairs at an FDR 5% level ( $P < 1.04 \times 10^{-4}$ ), spanning conditions related to  
27 both the circulatory system and the musculoskeletal and connective tissue. Notably, an  
28 extended torso length was linked to an increased risk of several cardiovascular conditions,  
29 such as coronary atherosclerosis and myocardial infarction ( $|\beta| > 18.72$ ,  $P < 1.40 \times 10^{-3}$ , 5/8  
30 MR methods significant). Furthermore, longer torso length was linked to several  
31 musculoskeletal and connective tissue disorders, such as internal derangement of the  
32 knee and meniscus derangement ( $|\beta| > 21.20$ ,  $P < 1.49 \times 10^{-5}$ , 5/8 MR methods significant)

1 (Fig. 5A). We also uncovered potential causal effects of multiple organ diseases on DXA-  
2 derived skeleton traits. At an FDR 5% level ( $P < 1.04 \times 10^{-4}$ ), we found 4 significant results  
3 that mainly on connective tissue disorders. For example, systemic connective tissue  
4 disorders and other systemic involvement of connective tissue were associated with  
5 lower average tibia height ( $|\beta| > 0.0005$ ,  $P < 3.61 \times 10^{-5}$ , 5/8 MR methods significant) (Fig.  
6 5B and Table S6).

## 8 Discussion

9 Observational studies have identified numerous links between imaging-derived  
10 phenotypes and clinical outcomes. However, these associations are often influenced by  
11 residual confounding, complicating the accurate inference of causal effect sizes<sup>62</sup>. MR  
12 allows for the inference of causal relationships between exposure and outcome variables.  
13 MR leverages the natural and random assortment of genetic variants during meiosis,  
14 making these variants ideal instrumental variables for discerning causal effects. In the  
15 present study, we evaluated the causal links between 402 multi-organ imaging traits and  
16 clinical outcomes through bidirectional MR. To circumvent the issue of sample overlap<sup>63</sup>,  
17 which can bias the causal effect and has been overlooked in many current MR-based  
18 studies, we used a two-sample MR design and sourced our imaging and clinical data from  
19 different large-scale cohorts.

20  
21 The interconnected nature of our organ systems suggested that diseases often affect  
22 more than one part of the human body<sup>35,36,61,64</sup>. The brain and heart are particularly  
23 critical, with the brain controlling a variety of functions, including reactions, emotions,  
24 vision, memory, and cognition<sup>65,66</sup>, while the heart acts pumps oxygen and nutrient-rich  
25 blood to other organs. Dysfunctions in various organs can potentially have detrimental  
26 effects on the brain and heart, and vice versa. Besides connections to the brain and heart,  
27 we also uncovered many other causal relationships across different organs. In this causal  
28 discovery research, we implemented stringent criteria for selecting significant causal pairs  
29 (Methods), with the goal being to ensure that all reported findings are statistically robust  
30 and capable of offering potential biological insights. Consequently, the absence of certain  
31 causal pairs in our study does not imply a lack of causal relationships. Moreover, our  
32 findings should be interpreted carefully in the context of known biology. Whereas some

1 causal pairs are highly plausible and predictable based on current knowledge, many are  
2 novel and unexpected. These should stimulate further research to discern potential  
3 mechanistic pathways. A visualization of the interactions across different organ systems  
4 can be found in **Figure 1B**. We will discuss our findings in more detail below.

5

#### 6 *Intra-brain causal connections.*

7 As expected, alterations in brain structure and function were found to be closely linked  
8 with brain disorders, with some of these relationships appearing to be bidirectional. We  
9 consistently identified causal connections between brain imaging traits and a variety of  
10 psychiatric disorders or neurological diseases, such as Alzheimer's disease, dementia,  
11 mood disorder, and sleep apnea. For example, AD and dementia had an impact on fMRI  
12 traits, which were primarily observed as indicators of AD and dementia. Prior studies have  
13 consistently reported that resting fMRI connectivity patterns are disrupted in patients  
14 with Alzheimer's disease<sup>67,68</sup>, particularly in brain regions involved in memory and  
15 cognitive function<sup>69,70</sup>. DTI abnormalities were found to be a precursor or an early sign of  
16 brain pathology that could lead to brain-related disorders<sup>71,72</sup>.

17

#### 18 *Brain-heart causal connections.*

19 Despite the increasing number of association studies investigating the brain-heart  
20 interaction<sup>40,73</sup>, causal genetic links within these systems remain largely uncharted. In this  
21 study, we identified causal connections from hypertension to DTI parameters in multiple  
22 white matter tracts, including the SCR, BCC, and GCC. Additionally, hypertension had  
23 causal effects on regional brain volumes and fMRI traits, such as the mean activity within  
24 the orbito-affective network. These results could be attributed to the effects of  
25 hypertension on cerebral small vessel health<sup>74,75</sup>, leading to microvascular damage, which  
26 can disrupt white matter integrity, alter brain function observable in fMRI, and contribute  
27 to changes in brain structure, such as reduced regional volumes. Furthermore, elevated  
28 blood pressure may cause ischemia and impair the blood-brain barrier, contributing to  
29 neuroinflammation and neurodegeneration, reflected in these imaging traits<sup>76-79</sup>. Hence,  
30 effective management of hypertension through lifestyle adjustments and medication  
31 could help mitigate these adverse effects on the brain, which should be addressed in  
32 future studies.

1

2 We observed that heart structural measures, such as regional myocardial-wall thickness,  
3 exhibited potential causal effects on Alzheimer's disease. Based on current knowledge,  
4 this connection does not seem to have clear underlying biologic plausibility, and should  
5 be interpreted cautiously until further knowledge is available regarding the role of cardiac  
6 abnormalities in the pathogenesis of Alzheimer's disease, which is at present  
7 incompletely understood<sup>80,81</sup>. Causal connections were also detected from the brain to  
8 the heart. We found that mental or degenerative neurological disorders can affect CMR  
9 traits, such as mood disorder affecting regional myocardial-wall thickness. The reason  
10 behind it may be related to the stress response, which can lead to increased levels of  
11 stress hormones such as cortisol and adrenaline<sup>82,83</sup>. These hormones can cause an  
12 increase in blood pressure and heart rate, leading to hypertrophy (thickening) of the  
13 myocardial wall over time as the heart works harder to pump blood<sup>84,85</sup>. Mood disorders  
14 may also cause lifestyle changes (such as changes in dietary and physical activity patterns)  
15 that have deleterious effects on blood pressure and vascular function. Inflammation may  
16 also be involved, since mood disorders have been associated with increased levels of  
17 systemic inflammation, which is a known risk factor for various forms of cardiovascular  
18 disease<sup>86,87</sup>.

19

#### 20 *Bidirectional connections between the brain and abdominal organs.*

21 Brain disorders were found to influence multiple abdominal organs. For example, we  
22 found that degenerative neurological diseases, such as Alzheimer's disease and dementia  
23 may exert potential causal effects on several abdominal imaging traits, such as liver fat  
24 and volume, visceral/abdominal subcutaneous adipose tissue volume, as well as lung  
25 volume. Patients with Alzheimer's disease and dementia often require multiple  
26 medications to manage symptoms, including antipsychotics, antidepressants, and  
27 medications aimed at slowing cognitive decline. Some of these medications can have  
28 hepatotoxic effects or interact with other drugs in ways that might impact liver function.  
29 Regular monitoring through liver function tests is important for patients on long-term  
30 medication regimens. Alzheimer's disease and dementia also might lead to systemic  
31 inflammation<sup>88</sup>, which has been linked to abnormal intermediary metabolism, a key  
32 regulator of liver fat and function<sup>89</sup>. The connection between neurological disorders and

1 adipose tissue volume might be related to reduced physical activity<sup>90</sup> and corticosteroid  
2 medications<sup>91</sup>. The connection between Alzheimer's disease and lung phenotypes may be  
3 related to effects of neurological diseases on respiratory muscle weakness<sup>92,93</sup>. This  
4 weakness could subsequently influence lung volume and functionality. Similar to  
5 Alzheimer's disease and dementia, sleep apnea could also affect liver and adipose tissue.  
6 Whereas sleep apnea and liver/adipose tissue may have overlying common determinants,  
7 such as obesity, insulin resistance, decreased physical activity, and abnormal dietary  
8 patterns, sleep apnea may also impact various metabolic processes in its own right, which  
9 could contribute to further insulin resistance and fat accumulation in the liver. In addition  
10 to neurological diseases, our study revealed that alcohol use disorder can cause an  
11 increase in liver fat percentage. It is well documented that individuals suffering from  
12 alcohol use disorder are more prone to develop alcoholic fatty liver disease<sup>94</sup>.

13  
14 Conversely, brain imaging traits were causally affected by various diseases of other organs  
15 or systems. For example, we found that asthma influenced regional brain volumes.  
16 Interestingly, prior studies have demonstrated that individuals with asthma may have  
17 diminished cognitive function, including impaired memory and attention, as well as  
18 changes in brain activity patterns during cognitive tasks<sup>95,96</sup>. Anxiety, stress, and  
19 depression, which are often experienced by individuals with asthma, can also result in  
20 alterations to brain structure. Notably, autoimmune diseases (as defined by FinnGen<sup>27</sup>)  
21 impacted brain imaging traits, such as DTI parameters of the SCR. Multiple sclerosis, an  
22 autoimmune disease affecting the central nervous system, can cause damage to the  
23 myelin sheath that surrounds axons and can occur in various brain regions<sup>97,98</sup>, including  
24 the internal capsule. This damage can disrupt neural connections passing through the  
25 anterior limb, leading to symptoms such as weakness, spasticity, and difficulty with  
26 balance and coordination. In rare autoimmune diseases, such as neuromyelitis optica<sup>99</sup>  
27 and autoimmune encephalitis, inflammation, and damage can occur in the brain. The  
28 resulting neurological symptoms can vary based on the severity and location of the  
29 damage<sup>100,101</sup>. Additionally, autoimmune diseases causing systemic inflammation, such as  
30 rheumatoid arthritis and lupus, could potentially affect the brain<sup>102</sup> and white matter  
31 tracts<sup>103,104</sup>. Chronic inflammation can lead to changes in the microstructure of white  
32 matter tracts, resulting in alterations in neural connectivity and function<sup>105,106</sup>.

1

2 *Intra-heart causal connections.*

3 Bidirectional causal relationships were observed between cardiovascular diseases and  
4 CMR traits. Hypertension was found to causally influence several CMR traits across  
5 different heart chambers and aorta regions. Conversely, alterations in CMR traits were  
6 contribute causally to heart diseases. These findings are well-aligned with our current  
7 understanding of the effects of hypertension on the heart. For example, hypertension can  
8 cause changes in the heart's structure and function due to increased afterload, leading to  
9 left ventricular hypertrophy and changes in left atrial size,<sup>107,108</sup> which can in turn  
10 contribute to the development of various complications, including atrial fibrillation, heart  
11 failure, and stroke<sup>109</sup>. Additionally, changes in cardiac structure might influence blood  
12 pressure regulation, since from a hemodynamic standpoint, blood pressure is the direct  
13 result of interactions between the cardiac pump and its coupled vascular load<sup>110</sup>.

14

15 *Causal connections between the heart and abdominal organs.*

16 Heart health was found to be causally linked with various multi-organ imaging traits or  
17 diseases. For example, liver fat was linked to multiple heart-related diseases, such as  
18 coronary atherosclerosis. This may be due to the key role of the liver in intermediary and  
19 lipoprotein metabolism, both of which are known contributors to the pathogenesis of  
20 atherosclerotic vascular disease. Additionally, heart failure was observed to cause an  
21 increase in spleen volume. The latter could be due to venous stasis and venous  
22 hypertension, which is a known consequence of heart failure. Indeed, increased venous  
23 pressure can lead to spleen enlargement, a condition known as splenomegaly<sup>111</sup>.  
24 Conversely, we found larger spleen volume to exhibit a causal effect on heart failure, a  
25 causal connection that is more difficult to interpret based on current knowledge, and  
26 which should stimulate further research. The pancreas also had causal effects on the  
27 cardiovascular system. For example, excess pancreas fat was associated with a higher risk  
28 of developing deep vein thrombosis of the lower extremities and pulmonary embolism.  
29 Pancreatic steatosis, a condition where fat accumulates in the pancreas, is linked with  
30 several metabolic abnormalities, including insulin resistance and inflammation, which can  
31 contribute to the development of cardiovascular diseases<sup>112,113</sup>.

32

1 *Causal connections between metabolic disorders and multiple organs.*

2 Diabetes was found to have an adverse impact on heart structural variations in AAO, RV,  
3 and LV. Multiple pathways may account for these causal associations, such as diabetic  
4 cardiomyopathy<sup>114</sup>, microvascular dysfunction<sup>115,116</sup>, and metabolic disturbances<sup>117</sup>.  
5 Diabetes can also affect the fat accumulation in the liver and pancreas. The liver plays a  
6 crucial role in managing glucose and fat metabolism. In the face of insulin resistance, the  
7 liver can accumulate fat, leading to non-alcoholic fatty liver disease. Insulin resistance  
8 prompts the liver to increase glucose production, contributing to high blood sugar levels,  
9 while also interfering with the liver's ability to process fat, leading to fat accumulation.  
10 Fat accumulation is not limited to the liver; it can also occur in the pancreas. The pancreas  
11 is sensitive to the metabolic changes induced by insulin resistance and obesity. Excess fat  
12 within the pancreas may affect its function, particularly the insulin-producing beta cells.  
13 Studies suggest that fat accumulation in the pancreas can impair insulin secretion<sup>118,119</sup>,  
14 exacerbating the cycle of insulin resistance and beta-cell dysfunction seen in type 2  
15 diabetes. Additionally, the excess fat (especially in the form of triglycerides) within the  
16 pancreas can lead to beta-cell dysfunction<sup>120</sup>. This dysfunction further impairs the body's  
17 ability to produce and regulate insulin effectively, worsening glucose control<sup>121-123</sup>.

18

19 *Skeleton DXA traits.*

20 We found genetic causal connections between DXA-derived skeleton traits and multiple  
21 organ diseases. MR typically reflects long-term effects rather than immediate impacts,  
22 making it a highly suitable method to measure causal effects related to the skeletal  
23 system. This is because skeletal traits are less prone to rapid modifications over short  
24 periods. Skeletal traits were shown to be potentially causally affected by musculoskeletal  
25 and connective disorders, which might have multiple pathways, such as altered bone  
26 density<sup>124</sup>, abnormal bone growth and formation, as well as inflammatory conditions.  
27 Conversely, skeletal disorders could contribute to numerous organ diseases, with heart  
28 conditions being the most prevalent in our analysis. However, the precise underlying  
29 mechanisms of these potentially causal connection require further study.

30

31 *Limitations and conclusions.*



1 Our study has several limitations. First, our GWAS summary statistics were sourced from  
2 publicly available databases. Thus, we could not evaluate the impact of unobserved  
3 confounders, such as population stratification, on our results. Second, a common  
4 limitation that most existing MR methods share is that they require several model  
5 assumptions. This may result in model misspecifications and issues related to data  
6 heterogeneity when integrating data from different data resources<sup>125</sup>. We have  
7 systematically applied quality control measures and performed sensitivity analyses in our  
8 study. Future research implementing more advanced MR methods may relax some of  
9 these model assumptions<sup>126,127</sup>. Furthermore, MR studies are designed to examine the  
10 effects of lifetime exposure factors on outcomes, not interventions within a specified  
11 period. As a result, our findings may be interpreted differently than the rigorous results  
12 obtained from randomized controlled trials. Moreover, our findings have varying degrees  
13 of biologic plausibility based on current knowledge. They should therefore be interpreted  
14 accordingly, and reinterpreted as new mechanistic knowledge becomes available.

15

16 In conclusion, we used two-sample bidirectional MR analyses to comprehensively explore  
17 the multi-organ causal connections between 372 clinical outcomes and 402 image-  
18 derived phenotypes of various organ systems. Our results revealed robust genetic  
19 evidence supporting causal connections within and across multiple organs. These findings  
20 will be useful in understanding complex pathogenic mechanisms and will contribute to  
21 further mechanistic research and ultimately, to the early prediction and prevention of  
22 multi-organ diseases from a whole-body perspective.

23

## 24 **METHODS**

25 Methods are available in the **Methods** section.

26 *Note: One supplementary table zip file are available.*

27

## 28 **ACKNOWLEDGEMENTS**

29 Research reported in this publication was supported by the National Institute On Aging of  
30 the National Institutes of Health under Award Number RF1AG082938. The content is  
31 solely the responsibility of the authors and does not necessarily represent the official  
32 views of the National Institutes of Health. The study has also been partially supported by

1 funding from the Wharton Dean's Research Fund, Analytics at Wharton, and Purdue  
2 Statistics Department. Assistance for this project was also provided by the UNC  
3 Intellectual and Developmental Disabilities Research Center (NICHD; P50 HD103573). This  
4 research has been conducted using summary-level data from the UK Biobank study and  
5 the FinnGen research project. We would like to thank the individuals who represented  
6 themselves in the UK Biobank and FinnGen studies for their participation and the research  
7 teams for their efforts in collecting, processing, and disseminating these datasets. We  
8 would like to thank the research computing groups at the University of North Carolina at  
9 Chapel Hill, Purdue University, and the Wharton School of the University of Pennsylvania  
10 for providing computational resources and support that have contributed to these  
11 research results.

12

### 13 **AUTHOR CONTRIBUTIONS**

14 J.S. and B.Z. designed the study. J.S., C.C., B.L., Z. F., X.Y., Y.Y, X.W., and Y.L. analyzed the  
15 data. R.Z. and J.C. helped interpret findings. B.X., T.L., and H.Z. provided feedback on the  
16 results. J.S. and B.Z. wrote the manuscript with feedback from all authors.

17

### 18 **COMPETING FINANCIAL INTERESTS**

19 The authors declare no competing financial interests.

20

### 21 **REFERENCES**

- 22 1. Buckner, R.L., *et al.* Molecular, structural, and functional characterization of  
23 Alzheimer's disease: evidence for a relationship between default activity,  
24 amyloid, and memory. *Journal of neuroscience* **25**, 7709-7717 (2005).
- 25 2. Pennell, D.J., *et al.* Clinical indications for cardiovascular magnetic resonance  
26 (CMR): Consensus Panel report. *European heart journal* **25**, 1940-1965 (2004).
- 27 3. Kun, E., *et al.* The genetic architecture and evolution of the human skeletal form.  
28 *Science* **381**, eadf8009 (2023).
- 29 4. Petersen, S.E., *et al.* UK Biobank's cardiovascular magnetic resonance protocol.  
30 *Journal of cardiovascular magnetic resonance* **18**, 1-7 (2015).
- 31 5. Littlejohns, T.J., Sudlow, C., Allen, N.E. & Collins, R. UK Biobank: opportunities for  
32 cardiovascular research. *European heart journal* **40**, 1158-1166 (2019).

- 1 6. Miller, K.L., *et al.* Multimodal population brain imaging in the UK Biobank  
2 prospective epidemiological study. *Nature Neuroscience* **19**, 1523-1536 (2016).
- 3 7. Thompson, P.M., *et al.* ENIGMA and global neuroscience: A decade of large-scale  
4 studies of the brain in health and disease across more than 40 countries.  
5 *Translational psychiatry* **10**, 1-28 (2020).
- 6 8. Liu, Y., *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI  
7 using deep learning. *Elife* **10**, e65554 (2021).
- 8 9. Smith, S.M. & Nichols, T.E. Statistical challenges in “big data” human  
9 neuroimaging. *Neuron* **97**, 263-268 (2018).
- 10 10. Tian, Y.E., *et al.* Heterogeneous aging across multiple organ systems and  
11 prediction of chronic disease and mortality. *Nature Medicine* **29**, 1221-1231  
12 (2023).
- 13 11. Taschler, B., Smith, S.M. & Nichols, T.E. Causal inference on neuroimaging data  
14 with Mendelian randomisation. *NeuroImage*, 119385 (2022).
- 15 12. Sanderson, E., *et al.* Mendelian randomization. *Nature Reviews Methods Primers*  
16 **2**, 1-21 (2022).
- 17 13. Pingault, J.-B., *et al.* Using genetic data to strengthen causal inference in  
18 observational research. *Nature Reviews Genetics* **19**, 566-580 (2018).
- 19 14. Aung, N., *et al.* Genome-wide analysis of left ventricular image-derived  
20 phenotypes identifies fourteen loci associated with cardiac morphogenesis and  
21 heart failure development. *Circulation* **140**, 1318-1330 (2019).
- 22 15. Córdova-Palomera, A., *et al.* Cardiac Imaging of Aortic Valve Area From 34 287  
23 UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic  
24 Comorbidity With Multiple Disease Phenotypes. *Circulation: Genomic and*  
25 *Precision Medicine* **13**, e003014 (2020).
- 26 16. Meyer, H.V., *et al.* Genetic and functional insights into the fractal structure of the  
27 heart. *Nature* **584**, 589-594 (2020).
- 28 17. Pirruccello, J.P., *et al.* Analysis of cardiac magnetic resonance imaging in 36,000  
29 individuals yields genetic insights into dilated cardiomyopathy. *Nature*  
30 *communications* **11**, 1-10 (2020).
- 31 18. Pirruccello, J.P., *et al.* Genetic analysis of right heart structure and function in  
32 40,000 people. *Nature genetics* **54**, 792-803 (2022).

- 1 19. Thanaj, M., *et al.* Genetic and environmental determinants of diastolic heart  
2 function. *Nature cardiovascular research* **1**, 361-371 (2022).
- 3 20. Elliott, L.T., *et al.* Genome-wide association studies of brain imaging phenotypes  
4 in UK Biobank. *Nature* **562**, 210-216 (2018).
- 5 21. Zhao, B., *et al.* Genome-wide association analysis of 19,629 individuals identifies  
6 variants influencing regional brain volumes and refines their genetic co-  
7 architecture with cognitive and mental health traits. *Nature genetics* **51**, 1637-  
8 1644 (2019).
- 9 22. Smith, S.M., *et al.* An expanded set of genome-wide association studies of brain  
10 imaging phenotypes in UK Biobank. *Nature neuroscience* **24**, 737-745 (2021).
- 11 23. Zhao, B., *et al.* Common genetic variation influencing human white matter  
12 microstructure. *Science* **372**, eabf3736 (2021).
- 13 24. Grasby, K.L., *et al.* The genetic architecture of the human cerebral cortex. *Science*  
14 **367**, eaay6690 (2020).
- 15 25. Zhao, B., *et al.* Genetic influences on the intrinsic and extrinsic functional  
16 organizations of the cerebral cortex. *medRxiv*, 2021.2007. 2027.21261187  
17 (2021).
- 18 26. Watanabe, K., *et al.* A global overview of pleiotropy and genetic architecture in  
19 complex traits. *Nature genetics* **51**, 1339-1348 (2019).
- 20 27. Kurki, M.I., *et al.* FinnGen provides genetic insights from a well-phenotyped  
21 isolated population. *Nature* **613**, 508-518 (2023).
- 22 28. Flynn, B.I., *et al.* Deep learning based phenotyping of medical images improves  
23 power for gene discovery of complex disease. *medRxiv*, 2023.2003.  
24 2007.23286909 (2023).
- 25 29. Guo, J., *et al.* Mendelian randomization analyses support causal relationships  
26 between brain imaging-derived phenotypes and risk of psychiatric disorders.  
27 *Nature Neuroscience* **25**, 1519-1527 (2022).
- 28 30. Chen, X., *et al.* Kidney damage causally affects the brain cortical structure: a  
29 Mendelian randomization study. *EBioMedicine* **72**, 103592 (2021).
- 30 31. Williams, J.A., *et al.* Inflammation and brain structure in schizophrenia and other  
31 neuropsychiatric disorders: a Mendelian randomization study. *JAMA psychiatry*  
32 **79**, 498-507 (2022).

- 1 32. Topiwala, A., *et al.* Associations between moderate alcohol consumption, brain  
2 iron, and cognition in UK Biobank participants: observational and mendelian  
3 randomization analyses. *PLoS medicine* **19**, e1004039 (2022).
- 4 33. Holmes, M.V., *et al.* Mendelian randomization of blood lipids for coronary heart  
5 disease. *European heart journal* **36**, 539-550 (2015).
- 6 34. Lamina, C. & Kronenberg, F. Estimation of the required lipoprotein (a)-lowering  
7 therapeutic effect size for reduction in coronary heart disease outcomes: a  
8 Mendelian randomization analysis. *JAMA cardiology* **4**, 575-579 (2019).
- 9 35. Skou, S.T., *et al.* Multimorbidity. *Nature Reviews Disease Primers* **8**, 48 (2022).
- 10 36. Langenberg, C., Hingorani, A.D. & Whitty, C.J. Biological and functional  
11 multimorbidity—from mechanisms to management. *Nature Medicine* **29**, 1649-  
12 1657 (2023).
- 13 37. Sudlow, C., *et al.* UK biobank: an open access resource for identifying the causes  
14 of a wide range of complex diseases of middle and old age. *PLoS medicine* **12**,  
15 e1001779 (2015).
- 16 38. Bijsterbosch, J., *et al.* Investigations into within-and between-subject resting-  
17 state amplitude variations. *Neuroimage* **159**, 57-69 (2017).
- 18 39. Bai, W., *et al.* A population-based phenome-wide association study of cardiac  
19 and aortic structure and function. *Nature Medicine* **26**, 1654-1662 (2020).
- 20 40. Zhao, B., *et al.* Heart-brain connections: Phenotypic and genetic insights from  
21 magnetic resonance images. *Science* **380**, abn6598 (2023).
- 22 41. Bowden, J., *et al.* A framework for the investigation of pleiotropy in two-sample  
23 summary data Mendelian randomization. *Statistics in medicine* **36**, 1783-1802  
24 (2017).
- 25 42. Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis  
26 with multiple genetic variants using summarized data. *Genetic epidemiology* **37**,  
27 658-665 (2013).
- 28 43. Bowden, J., *et al.* Improving the accuracy of two-sample summary-data  
29 Mendelian randomization: moving beyond the NOME assumption. *Int J*  
30 *Epidemiol* **48**, 728-742 (2019).

- 1 44. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid  
2 instruments: effect estimation and bias detection through Egger regression.  
3 *International journal of epidemiology* **44**, 512-525 (2015).
- 4 45. Hartwig, F.P., Davey Smith, G. & Bowden, J. Robust inference in summary data  
5 Mendelian randomization via the zero modal pleiotropy assumption.  
6 *International journal of epidemiology* **46**, 1985-1998 (2017).
- 7 46. Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. Consistent estimation in  
8 Mendelian randomization with some invalid instruments using a weighted  
9 median estimator. *Genetic epidemiology* **40**, 304-314 (2016).
- 10 47. Ye, T., Shao, J. & Kang, H. Debiased inverse-variance weighted estimator in two-  
11 sample summary-data Mendelian randomization. *The Annals of statistics* **49**,  
12 2079-2100 (2021).
- 13 48. Zhao, Q., Wang, J., Hemani, G., Bowden, J. & Small, D.S. Statistical inference in  
14 two-sample summary-data Mendelian randomization using robust adjusted  
15 profile score. *The Annals of Statistics* **48**, 1742-1769 (2020).
- 16 49. Wang, J., *et al.* Causal inference for heritable phenotypic risk factors using  
17 heterogeneous genetic instruments. *PLoS genetics* **17**, e1009575 (2021).
- 18 50. Bennett, I.J., Madden, D.J., Vaidya, C.J., Howard, D.V. & Howard Jr, J.H. Age-  
19 related differences in multiple measures of white matter integrity: A diffusion  
20 tensor imaging study of healthy aging. *Human brain mapping* **31**, 378-390  
21 (2010).
- 22 51. Segmentation, A.H.A.W.G.o.M., *et al.* Standardized myocardial segmentation and  
23 nomenclature for tomographic imaging of the heart: a statement for healthcare  
24 professionals from the Cardiac Imaging Committee of the Council on Clinical  
25 Cardiology of the American Heart Association. *Circulation* **105**, 539-542 (2002).
- 26 52. Stratos, C., Stefanadis, C., Kallikazaros, I., Boudoulas, H. & Toutouzas, P.  
27 Ascending aorta distensibility abnormalities in hypertensive patients and  
28 response to nifedipine administration. *The American journal of medicine* **93**, 505-  
29 512 (1992).
- 30 53. Asmar, R., *et al.* Aortic distensibility in normotensive, untreated and treated  
31 hypertensive patients. *Blood pressure* **4**, 48-54 (1995).

- 1 54. Nabati, M., Namazi, S.S., Yazdani, J. & Sharif Nia, H. Relation between aortic  
2 stiffness index and distensibility with age in hypertensive patients. *International*  
3 *journal of general medicine*, 297-303 (2020).
- 4 55. Berman, M.N., Tupper, C. & Bhardwaj, A. Physiology, Left Ventricular Function.  
5 (2019).
- 6 56. Kim, D.-Y. & Camilleri, M. Serotonin: a mediator of the brain–gut connection.  
7 *Official journal of the American College of Gastroenterology| ACG* **95**, 2698-2709  
8 (2000).
- 9 57. Jones, M., Dilley, J., Drossman, D. & Crowell, M. Brain–gut connections in  
10 functional GI disorders: anatomic and physiologic relationships.  
11 *Neurogastroenterology & Motility* **18**, 91-103 (2006).
- 12 58. Keefer, L., *et al.* A Rome working team report on brain-gut behavior therapies for  
13 disorders of gut-brain interaction. *Gastroenterology* **162**, 300-315 (2022).
- 14 59. Xie, Z., Tong, S., Chu, X., Feng, T. & Geng, M. Chronic kidney disease and  
15 cognitive impairment: The kidney-brain axis. *Kidney Diseases* **8**, 275-285 (2022).
- 16 60. de Donato, A., Buonincontri, V., Borriello, G., Martinelli, G. & Mone, P. The  
17 dopamine system: insights between kidney and brain. *Kidney and Blood Pressure*  
18 *Research* **47**, 493-505 (2022).
- 19 61. McCracken, C., *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis  
20 in UK Biobank participants. *Nature Communications* **13**, 7839 (2022).
- 21 62. Walker, V.M., Zheng, J., Gaunt, T.R. & Smith, G.D. Phenotypic Causal Inference  
22 Using Genome-Wide Association Study Data: Mendelian Randomization and  
23 Beyond. *Annu Rev Biomed Data Sci* **5**, 1-17 (2022).
- 24 63. Burgess, S., Davies, N.M. & Thompson, S.G. Bias due to participant overlap in  
25 two-sample Mendelian randomization. *Genetic epidemiology* **40**, 597-608 (2016).
- 26 64. Jaggi, A., *et al.* A structural heart-brain axis mediates the association between  
27 cardiovascular risk and cognitive function. *Imaging Neuroscience* **2**, 1-18 (2024).
- 28 65. Berridge, K.C. & Kringelbach, M.L. Pleasure systems in the brain. *Neuron* **86**, 646-  
29 664 (2015).
- 30 66. Bressler, S.L. & Menon, V. Large-scale brain networks in cognition: emerging  
31 methods and principles. *Trends Cogn Sci* **14**, 277-290 (2010).

- 1 67. Wang, K., *et al.* Altered functional connectivity in early Alzheimer's disease: A  
2 resting-state fMRI study. *Human brain mapping* **28**, 967-978 (2007).
- 3 68. Sorg, C., *et al.* Selective changes of resting-state networks in individuals at risk  
4 for Alzheimer's disease. *Proceedings of the National Academy of Sciences* **104**,  
5 18760-18765 (2007).
- 6 69. Ranasinghe, K.G., *et al.* Regional functional connectivity predicts distinct  
7 cognitive impairments in Alzheimer's disease spectrum. *NeuroImage: Clinical* **5**,  
8 385-395 (2014).
- 9 70. Pini, L., *et al.* A low-dimensional cognitive-network space in Alzheimer's disease  
10 and frontotemporal dementia. *Alzheimer's Research & Therapy* **14**, 199 (2022).
- 11 71. Torso, M., *et al.* In vivo cortical diffusion imaging relates to Alzheimer's disease  
12 neuropathology. *Alzheimers Res Ther* **15**, 165 (2023).
- 13 72. Tu, M.-C., *et al.* Joint diffusional kurtosis magnetic resonance imaging analysis of  
14 white matter and the thalamus to identify subcortical ischemic vascular disease.  
15 *Scientific Reports* **14**, 2570 (2024).
- 16 73. Liu, W., *et al.* Brain–heart communication in health and diseases. *Brain Research*  
17 *Bulletin* (2022).
- 18 74. Walker, K.A., Power, M.C. & Gottesman, R.F. Defining the relationship between  
19 hypertension, cognitive decline, and dementia: a review. *Current hypertension*  
20 *reports* **19**, 1-16 (2017).
- 21 75. Zhang, H., *et al.* Reduced regional gray matter volume in patients with chronic  
22 obstructive pulmonary disease: a voxel-based morphometry study. *American*  
23 *Journal of Neuroradiology* **34**, 334-339 (2013).
- 24 76. Yang, C., Hawkins, K.E., Doré, S. & Candelario-Jalil, E. Neuroinflammatory  
25 mechanisms of blood-brain barrier damage in ischemic stroke. *American Journal*  
26 *of Physiology-Cell Physiology* **316**, C135-C153 (2019).
- 27 77. Carnevale, D., *et al.* Role of neuroinflammation in hypertension-induced brain  
28 amyloid pathology. *Neurobiology of aging* **33**, 205. e219-205. e229 (2012).
- 29 78. Haspula, D. & Clark, M.A. Neuroinflammation and sympathetic overactivity:  
30 Mechanisms and implications in hypertension. *Autonomic Neuroscience* **210**, 10-  
31 17 (2018).



- 1 79. Sweeney, M.D., Sagare, A.P. & Zlokovic, B.V. Blood–brain barrier breakdown in  
2 Alzheimer disease and other neurodegenerative disorders. *Nature Reviews*  
3 *Neurology* **14**, 133-150 (2018).
- 4 80. Niedermeyer, E. Alzheimer disease: caused by primary deficiency of the cerebral  
5 blood flow. *Clinical EEG and neuroscience* **37**, 175-177 (2006).
- 6 81. Kisler, K., Nelson, A.R., Montagne, A. & Zlokovic, B.V. Cerebral blood flow  
7 regulation and neurovascular dysfunction in Alzheimer disease. *Nature Reviews*  
8 *Neuroscience* **18**, 419-434 (2017).
- 9 82. Chu, B., Marwaha, K., Sanvictores, T. & Ayers, D. Physiology, stress reaction. in  
10 *StatPearls [Internet]* (StatPearls Publishing, 2021).
- 11 83. Charmandari, E., Tsigos, C. & Chrousos, G. Endocrinology of the stress response.  
12 *Annu. Rev. Physiol.* **67**, 259-284 (2005).
- 13 84. Colao, A., Marzullo, P., Di Somma, C. & Lombardi, G. Growth hormone and the  
14 heart. *Clinical endocrinology* **54**, 137-154 (2001).
- 15 85. Fazio, S., *et al.* Growth hormone and heart performance: a novel mechanism of  
16 cardiac wall stress regulation in humans. *European Heart Journal* **18**, 340-347  
17 (1997).
- 18 86. Black, P.H. & Garbutt, L.D. Stress, inflammation and cardiovascular disease.  
19 *Journal of psychosomatic research* **52**, 1-23 (2002).
- 20 87. Libby, P. Inflammation and cardiovascular disease mechanisms. *The American*  
21 *journal of clinical nutrition* **83**, 456S-460S (2006).
- 22 88. Holmes, C. Systemic inflammation and Alzheimer's disease. *Neuropathology and*  
23 *applied neurobiology* **39**, 51-68 (2013).
- 24 89. Laleman, W., Claria, J., Van der Merwe, S., Moreau, R. & Trebicka, J. Systemic  
25 inflammation and acute-on-chronic liver failure: too much, not enough.  
26 *Canadian Journal of Gastroenterology and Hepatology* **2018**(2018).
- 27 90. Scherder, E.J., Bogen, T., Eggermont, L.H., Hamers, J.P. & Swaab, D.F. The more  
28 physical inactivity, the more agitation in dementia. *Int Psychogeriatr* **22**, 1203-  
29 1208 (2010).
- 30 91. Peckett, A.J., Wright, D.C. & Riddell, M.C. The effects of glucocorticoids on  
31 adipose tissue lipid metabolism. *Metabolism* **60**, 1500-1510 (2011).

- 1 92. Polkey, M.I., Lyall, R.A., Moxham, J. & Leigh, P.N. Respiratory aspects of  
2 neurological disease. *Journal of Neurology, Neurosurgery & Psychiatry* **66**, 5-15  
3 (1999).
- 4 93. Pollock, R.D., Rafferty, G.F., Moxham, J. & Kalra, L. Respiratory muscle strength  
5 and training in stroke and neurology: a systematic review. *International Journal*  
6 *of Stroke* **8**, 124-130 (2013).
- 7 94. Kushner, T. & Cafardi, J. Chronic liver disease and COVID-19: alcohol use  
8 disorder/alcohol-associated liver disease, nonalcoholic fatty liver  
9 disease/nonalcoholic steatohepatitis, autoimmune liver disease, and  
10 compensated cirrhosis. *Clinical Liver Disease* **15**, 195 (2020).
- 11 95. Rhyou, H.-I. & Nam, Y.-H. Association between cognitive function and asthma in  
12 adults. *Annals of Allergy, Asthma & Immunology* **126**, 69-74 (2021).
- 13 96. Ray, M., Sano, M., Wisnivesky, J.P., Wolf, M.S. & Federman, A.D. Asthma control  
14 and cognitive function in a cohort of elderly adults. *Journal of the American*  
15 *Geriatrics Society* **63**, 684-691 (2015).
- 16 97. Alvarez, J.I., Cayrol, R. & Prat, A. Disruption of central nervous system barriers in  
17 multiple sclerosis. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of*  
18 *Disease* **1812**, 252-264 (2011).
- 19 98. Krupp, L.B., *et al.* International Pediatric Multiple Sclerosis Study Group criteria  
20 for pediatric multiple sclerosis and immune-mediated central nervous system  
21 demyelinating disorders: revisions to the 2007 definitions. *Multiple Sclerosis*  
22 *Journal* **19**, 1261-1267 (2013).
- 23 99. Huda, S., *et al.* Neuromyelitis optica spectrum disorders. *Clinical Medicine* **19**,  
24 169 (2019).
- 25 100. Kim, W., Kim, S.-H., Huh, S.-Y. & Kim, H.J. Brain abnormalities in neuromyelitis  
26 optica spectrum disorder. *Multiple sclerosis international* **2012**(2012).
- 27 101. Lancaster, E. The diagnosis and treatment of autoimmune encephalitis. *Journal*  
28 *of Clinical Neurology* **12**, 1-13 (2016).
- 29 102. Wartolowska, K., *et al.* Structural changes of the brain in rheumatoid arthritis.  
30 *Arthritis & Rheumatism* **64**, 371-379 (2012).

- 1 103. Kozora, E. & Filley, C.M. Cognitive dysfunction and white matter abnormalities in  
2 systemic lupus erythematosus. *Journal of the International Neuropsychological*  
3 *Society* **17**, 385-392 (2011).
- 4 104. Appenzeller, S., *et al.* Longitudinal analysis of gray and white matter loss in  
5 patients with systemic lupus erythematosus. *Neuroimage* **34**, 694-701 (2007).
- 6 105. Rosenberg, G.A. Inflammation and white matter damage in vascular cognitive  
7 impairment. *Stroke* **40**, S20-S23 (2009).
- 8 106. Raj, D., *et al.* Increased white matter inflammation in aging-and Alzheimer's  
9 disease brain. *Frontiers in molecular neuroscience* **10**, 206 (2017).
- 10 107. Gerdts, E., *et al.* Correlates of left atrial size in hypertensive patients with left  
11 ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in  
12 Hypertension (LIFE) Study. *Hypertension* **39**, 739-743 (2002).
- 13 108. Eshoo, S., Ross, D.L. & Thomas, L. Impact of mild hypertension on left atrial size  
14 and function. *Circulation: Cardiovascular Imaging* **2**, 93-99 (2009).
- 15 109. Sanfilippo, A.J., *et al.* Atrial enlargement as a consequence of atrial fibrillation. A  
16 prospective echocardiographic study. *Circulation* **82**, 792-797 (1990).
- 17 110. Saheera, S. & Krishnamurthy, P. Cardiovascular Changes Associated with  
18 Hypertensive Heart Disease and Aging. *Cell Transplant* **29**, 963689720920830  
19 (2020).
- 20 111. Hiraiwa, H., *et al.* Clinical significance of spleen size in patients with heart failure.  
21 *European Heart Journal* **42**, ehab724. 0756 (2021).
- 22 112. Ormazabal, V., *et al.* Association between insulin resistance and the  
23 development of cardiovascular disease. *Cardiovascular diabetology* **17**, 1-14  
24 (2018).
- 25 113. Shah, A., Mehta, N. & Reilly, M.P. Adipose inflammation, insulin resistance, and  
26 cardiovascular disease. *Journal of Parenteral and Enteral Nutrition* **32**, 638-644  
27 (2008).
- 28 114. Boudina, S. & Abel, E.D. Diabetic cardiomyopathy, causes and effects. *Reviews in*  
29 *Endocrine and Metabolic Disorders* **11**, 31-39 (2010).
- 30 115. Horton, W.B. & Barrett, E.J. Microvascular dysfunction in diabetes mellitus and  
31 cardiometabolic disease. *Endocrine reviews* **42**, 29-55 (2021).

- 1 116. Kibel, A., *et al.* Coronary microvascular dysfunction in diabetes mellitus. *Journal*  
2 *of International Medical Research* **45**, 1901-1929 (2017).
- 3 117. Fuentes-Antrás, J., *et al.* Targeting metabolic disturbance in the diabetic heart.  
4 *Cardiovascular Diabetology* **14**, 1-11 (2015).
- 5 118. Wagner, R., *et al.* Metabolic implications of pancreatic fat accumulation. *Nat Rev*  
6 *Endocrinol* **18**, 43-54 (2022).
- 7 119. Yaney, G.C. & Corkey, B.E. Fatty acid metabolism and insulin secretion in  
8 pancreatic beta cells. *Diabetologia* **46**, 1297-1312 (2003).
- 9 120. Dłudla, P.V., *et al.* Pancreatic beta-cell dysfunction in type 2 diabetes:  
10 Implications of inflammation and oxidative stress. *World J Diabetes* **14**, 130-146  
11 (2023).
- 12 121. Kocaturk, E., Kar, E., Kusku Kiraz, Z. & Alatas, O. Insulin resistance and pancreatic  
13 beta cell dysfunction are associated with thyroid hormone functions: A cross-  
14 sectional hospital-based study in Turkey. *Diabetes Metab Syndr* **14**, 2147-2151  
15 (2020).
- 16 122. Meeks, K.A.C., Adeyemo, A. & Agyemang, C. Beta-cell dysfunction and insulin  
17 resistance in relation to abnormal glucose tolerance in African populations: can  
18 we afford to ignore the diversity within African populations? *BMJ Open Diabetes*  
19 *Res Care* **10**(2022).
- 20 123. Bonora, E., *et al.* Insulin resistance and beta-cell dysfunction in newly diagnosed  
21 type 2 diabetes: Expression, aggregation and predominance. Verona Newly  
22 Diagnosed Type 2 Diabetes Study 10. *Diabetes Metab Res Rev* **38**, e3558 (2022).
- 23 124. Whalen, R., Carter, D. & Steele, C. Influence of physical activity on the regulation  
24 of bone density. *Journal of biomechanics* **21**, 825-837 (1988).
- 25 125. Zhao, Q., Wang, J., Spiller, W., Bowden, J. & Small, D.S. Two-sample instrumental  
26 variable analyses using heterogeneous samples. *Statistical Science* **34**, 317-333  
27 (2019).
- 28 126. Cui, R., *et al.* Improving fine-mapping by modeling infinitesimal effects. *bioRxiv*,  
29 2022.2010.2021.513123 (2022).
- 30 127. Xue, H., Shen, X. & Pan, W. Causal Inference in Transcriptome-Wide Association  
31 Studies with Invalid Instruments and GWAS Summary Data. *Journal of the*  
32 *American Statistical Association*, 1-27 (2023).

- 1 128. Tseng, W.Y., Su, M.Y. & Tseng, Y.H. Introduction to Cardiovascular Magnetic  
2 Resonance: Technical Principles and Clinical Applications. *Acta Cardiol Sin* **32**,  
3 129-144 (2016).
- 4 129. Pennell, D.J. Cardiovascular magnetic resonance. *Circulation* **121**, 692-705  
5 (2010).
- 6 130. Bai, W., *et al.* Automated cardiovascular magnetic resonance image analysis with  
7 fully convolutional networks. *Journal of Cardiovascular Magnetic Resonance* **20**,  
8 1-12 (2018).
- 9 131. Bai, W., *et al.* Recurrent neural networks for aortic image sequence  
10 segmentation with sparse annotations. *International conference on medical*  
11 *image computing and computer-assisted intervention*, 586-594 (2018).
- 12 132. Miller, K.L., *et al.* Multimodal population brain imaging in the UK Biobank  
13 prospective epidemiological study. *Nat Neurosci* **19**, 1523-1536 (2016).
- 14 133. Zhao, B., *et al.* Heritability of regional brain volumes in large-scale neuroimaging  
15 and genetic studies. *Cerebral Cortex* **29**, 2904-2914 (2019).
- 16 134. Zhao, B., *et al.* Large-scale GWAS reveals genetic architecture of brain white  
17 matter microstructure and genetic overlap with cognitive and mental health  
18 traits (n= 17,706). *Molecular psychiatry* **26**, 3943-3955 (2021).
- 19 135. Avants, B.B., *et al.* A reproducible evaluation of ANTs similarity metric  
20 performance in brain image registration. *Neuroimage* **54**, 2033-2044 (2011).
- 21 136. Jahanshad, N., *et al.* Multi-site genetic analysis of diffusion images and voxelwise  
22 heritability analysis: A pilot project of the ENIGMA-DTI working group.  
23 *Neuroimage* **81**, 455-469 (2013).
- 24 137. Kochunov, P., *et al.* Multi-site study of additive genetic effects on fractional  
25 anisotropy of cerebral white matter: comparing meta and megaanalytical  
26 approaches for data pooling. *Neuroimage* **95**, 136-150 (2014).
- 27 138. Glasser, M.F., *et al.* A multi-modal parcellation of human cerebral cortex. *Nature*  
28 **536**, 171-178 (2016).
- 29 139. Ji, J.L., *et al.* Mapping the human brain's cortical-subcortical functional network  
30 organization. *Neuroimage* **185**, 35-57 (2019).

1 140. Bowden, J., *et al.* Improving the accuracy of two-sample summary-data  
2 Mendelian randomization: moving beyond the NOME assumption. *International*  
3 *journal of epidemiology* **48**, 728-742 (2019).  
4

## 5 **METHODS**

### 6 **Multi-organ imaging traits.**

7 The imaging data were sourced from the UK Biobank (UKB) study, which enrolled  
8 approximately 500,000 individuals aged between 40 and 69 from 2006 to 2010  
9 (<https://www.ukbiobank.ac.uk/>). These multi-organ imaging data were collected from  
10 the ongoing UKB imaging study project ([https://www.ukbiobank.ac.uk/explore-your-](https://www.ukbiobank.ac.uk/explore-your-participation/contribute-further/imaging-study)  
11 [participation/contribute-further/imaging-study](https://www.ukbiobank.ac.uk/explore-your-participation/contribute-further/imaging-study)), which aims to collect brain, heart, and  
12 abdomen scans from 100,000 participants. Ethical approval for the UKB study was  
13 secured from the North West Multicentre Research Ethics Committee (approval number:  
14 11/NW/0382).  
15

16 Studies of brain and heart diseases usually rely on magnetic resonance imaging (MRI)  
17 scans, which are well-established clinical endophenotypes. Cardiovascular magnetic  
18 resonance imaging (CMR) is a set of MRI techniques that are designed to assess  
19 ventricular function, cardiovascular morphology, myocardial perfusion, and other cardiac  
20 functional and structural features<sup>128,129</sup>. They have been frequently used to reveal heart-  
21 related issues clinically. The CMR traits used in the paper were originally generated from  
22 the raw short-axis, long-axis, and aortic cine images using the state-of-the-art heart  
23 imaging segmentation and feature representation framework<sup>39,130,131</sup>. We divided the  
24 generated 82 CMR traits into 6 categories. The first two are aortic sections, namely  
25 ascending aorta (AAo) and descending aorta (DAo), which serve as the main ‘pipe’ in  
26 supplying blood to the entire body. The other four are the global measures of 4 cardiac  
27 chambers, including the left ventricle (LV), right ventricle (RV), left atrium (LA), and right  
28 atrium (RA), which altogether manage the heartbeat and blood flow. There are also some  
29 other traits, such as regional phenotypes of the left ventricle myocardial-wall thickness  
30 and strain (**Table S1**). The summary-level GWAS data of these 82 CMR traits were  
31 obtained from Zhao, et al.<sup>40</sup>.  
32

1 Brain MRI provides detailed information about brain structure and function<sup>132</sup>, such as  
2 abnormal growth, healthy aging, white matter diseases, structural issues, and functional  
3 abnormalities. In this paper, the summary-level GWAS data were collected from recent  
4 multi-modal image genetic studies, including regional brain volumes from structural  
5 MRI<sup>21,133</sup> (sMRI), diffusion tensor imaging (DTI) parameters from diffusion MRI<sup>23,134</sup> (dMRI),  
6 and functional activity (that is, amplitude<sup>38</sup>) and functional connectivity phenotypes from  
7 resting functional MRI<sup>25</sup> (resting fMRI). In sMRI, we used ANTs<sup>135</sup> to generate regional  
8 brain volumes for cortical and subcortical regions and global brain volume measures. In  
9 dMRI, we used the ENIGMA-DTI pipelines<sup>136,137</sup> to generate tract-averaged parameters  
10 for fractional anisotropy, mean diffusivity, axial diffusivity, radial diffusivity, and mode of  
11 anisotropy in major white matter tracts and across the whole brain. For resting fMRI, we  
12 extracted phenotypes from brain parcellation-based analysis. We used the Glasser360  
13 atlas<sup>138</sup>, which divided the cerebral cortex into 360 regions in 12 functional networks<sup>139</sup>.  
14 We considered 90 network-level resting fMRI phenotypes that evaluated interactions and  
15 spontaneous neural activity at rest.

16  
17 The 11 imaging traits from abdominal MRI were derived by Liu., et al<sup>8</sup> using deep learning  
18 methods in terms of volume, fat, and iron in several organs and tissues, such as the liver,  
19 spleen, kidney, lung, pancreas, and adipose tissue. Skeleton DXA traits, including all long  
20 bone lengths as well as hip and shoulder width, were derived by Kun, et al.<sup>3</sup> using deep  
21 learning methods on whole-body DXA images. All eight skeleton traits have been  
22 controlled for height.

23

#### 24 **FinnGen clinical endpoints.**

25 We used 372 clinical endpoints (304 with more than 10,000 cases and 68 more with at  
26 least 5000 cases) collected by the FinnGen project, which were selected from the R9  
27 release ([https://www.finnngen.fi/en/access\\_results](https://www.finnngen.fi/en/access_results)). Our initial criterion for selecting  
28 diseases was to include those with more than 10,000 cases. For certain significant  
29 diseases, such as Alzheimer's disease and neoplasm, we further relaxed the case number  
30 cutoff to 5,000. The 372 clinical endpoints covered diseases from various categories,  
31 namely, mental and behavioral disorders, diseases of the nervous system, diseases of the  
32 eye and adnexa, diseases of the genitourinary system, diseases of the circulatory systems,

1 endocrine, nutritional and metabolic disorders, diseases marked as autoimmune origin,  
2 diseases of the respiratory system, diseases of the digestive system, diseases of blood and  
3 blood-forming, diseases of the musculoskeletal system and connective tissue, as well as  
4 some other endpoints. The definitions can be found at <https://risteys.finregistry.fi/>. The  
5 FinnGen data used in our study was obtained from separate cohorts than those supplying  
6 imaging traits, which were derived from the UKB study, thus ensuring there was no  
7 sample overlap. Detailed information of these 372 clinical variables can be found in **Table**  
8 **S2**.

9

### 10 **Mendelian randomization analysis.**

11 We examined the genetic causal relationships between the 402 imaging traits (101 brain  
12 regional volume traits, 110 brain DTI parameters, 90 network-level fMRI phenotypes, 82  
13 CMR traits, 11 abdominal traits, and 8 skeleton DXA traits) and 372 clinical endpoints.  
14 Prior to conducting the Mendelian randomization (MR) analysis, we conducted standard  
15 preprocessing and quality control procedures. First, we selected genetic variants based  
16 on a significance threshold of  $5 \times 10^{-8}$  in the exposure GWAS data. To ensure the  
17 independence of the genetic variants used in MR, we implemented LD clumping with a  
18 window size of 10,000 and an  $r^2$  threshold of 0.01, using the 1000 Genomes European  
19 ancestry data as a reference panel. We used the TwoSampleMR package  
20 (<https://mrcieu.github.io/TwoSampleMR/>) for harmonization, which enabled us to  
21 accurately align alleles between the selected variants in the exposure and the reported  
22 effect on the outcome.

23

24 We assessed the performance of 8 MR methods, which included Inverse variance  
25 weighted (fixed effect), Inverse variance weighted (multiplicative random effect), MR-  
26 Egger, Simple Median, Weighted Median, Weighted Mode, DIVW, GRAPPLE, and MR-  
27 RAPS<sup>41,42,44-49,140</sup>, where MR Egger was used as the pleiotropy test and will not be included  
28 in the figures. To ensure the reliability of our results, we implemented several quality  
29 control procedures. We excluded causal estimates that relied on fewer than 6 genetic  
30 variants, as a larger number of genetic variants increases the statistical power of MR  
31 analysis<sup>47,48</sup>. We retained causal pairs that were significant in at least two out of the eight  
32 methods. We also screened for pleiotropy by using the MR-Egger intercept, the most used



1 method for testing the pleiotropy assumption. If a causal estimate failed the MR-Egger  
2 intercept test, we required that it have significant results in at least one of the robust MR  
3 methods, such as Weighted Median, Weighted Model, MR-RAPS, or GRAPPLE.  
4 Additionally, we require all the selected causal pairs to be significant in more than half of  
5 the methods.

6

### 7 **Code availability**

8 We made use of publicly available software and tools. Our analysis code will be made  
9 freely available at Zenodo.

10

### 11 **Data availability**

12 We used summary-level GWAS data in this study, which can be obtained from the  
13 FinnGen project ([https://www.finnngen.fi/en/access\\_results](https://www.finnngen.fi/en/access_results)), BIG-KP (<https://bigkp.org/>),  
14 Heart-KP (<https://heartkp.org/>), and project-specific resources are detailed in Liu., et al.<sup>8</sup>  
15 and Kun, et al.<sup>3</sup>.

16

### 17 **Figure legends**

#### 18 **Fig. 1 Overview of study design and findings.**

19 **(A).** An overview of our multi-organ imaging genetic study, investigating 372 clinical  
20 outcomes. We used diverse imaging traits including multi-modal brain, cardiac,  
21 abdominal, and skeletal DXA imaging to explore their relationships with the clinical  
22 endpoints. Our study encompasses a comprehensive range of brain imaging modalities,  
23 such as structural MRI, diffusion MRI, and resting-state fMRI. The cardiac imaging data  
24 comprise short-axis, long-axis, and aortic cine images. Volume, iron content, and percent  
25 fat were measured across 6 different abdominal organs and tissues, yielding in 11 image-  
26 derived abdominal phenotypes. Additionally, we included 8 skeleton imaging traits  
27 encompassing long bone lengths as well as hip and shoulder width. **(B).** A high-level  
28 summary of our bidirectional findings. The left panel displayed all the imaging traits that  
29 have been used in the study. The grey arrow demonstrates the main findings, such as the  
30 intra-brain, intra-heart, brain-heart, and brain-abdominal-organs causal connections. The  
31 right panel depicts the intricate web of causal interactions among various organs as

1 uncovered in our study. The width of an arrow corresponds to the volume of findings  
2 associated with it.

3

4 **Fig. 2 Selected genetic causal effects of clinical outcomes on brain imaging traits.**

5 We illustrated selected significant ( $P < 1.31 \times 10^{-4}$ ) putative causal genetic links from  
6 clinical endpoints (Exposure) to brain imaging traits (Outcome), with adjustment for  
7 multiple testing using the FDR procedure. (A). The causal effect of degenerative  
8 neurological diseases on brain imaging traits. (B). The causal effect of hypertension on  
9 brain imaging traits. (C). The causal effect of other diseases on brain imaging traits. (D).  
10 The causal effect of brain imaging traits on degenerative neurological diseases. The term  
11 'IDP Category' is used to signify the category of imaging traits, while '#IVs' stands for the  
12 number of genetic variants utilized as instrumental variables. Various MR methods and  
13 their associated regression coefficients are marked with different colors for easy  
14 identification. See **Table S1** for data resources on clinical endpoints and **Table S2** for data  
15 resources on imaging traits.

16

17 **Fig. 3 Selected genetic causal effects between heart imaging traits and clinical endpoints.**

18 (A). Selected significant ( $P < 6.95 \times 10^{-4}$ ) causal genetic links from heart-related diseases  
19 (Exposure) to heart imaging traits (Outcome) with adjustment for multiple testing using  
20 the FDR procedure. (B). Selected significant ( $P < 6.95 \times 10^{-4}$ ) causal genetic links from  
21 metabolic disorders (Exposure) to heart imaging traits (Outcome) with adjustment for  
22 multiple testing using the FDR procedure. (C). Selected significant ( $P < 6.95 \times 10^{-4}$ ) causal  
23 genetic links from brain disorders (Exposure) to heart imaging traits (Outcome) with  
24 adjustment for multiple testing using the FDR procedure. (D). Selected significant ( $P <$   
25  $6.95 \times 10^{-4}$ ) causal genetic links from heart imaging traits (Exposure) to heart-related  
26 diseases (Outcome) with adjustment for multiple testing using the FDR procedure. (E).  
27 Selected significant ( $P < 6.95 \times 10^{-4}$ ) causal genetic links from heart imaging traits  
28 (Exposure) to Alzheimer's disease (Outcome) with adjustment for multiple testing using  
29 the FDR procedure. The term 'IDP Category' is used to signify the category of imaging  
30 traits, while '#IVs' stands for the number of genetic variants utilized as instrumental  
31 variables. Various MR methods and their associated regression coefficients are marked

1 with different colors for easy identification. (F). A high-level summary of our findings. See  
2 **Table S1** for data resources of clinical endpoints and **Table S2** for data resources on  
3 imaging traits.

4

5 **Fig. 4 Selected genetic causal effects between abdominal imaging traits and clinical**  
6 **endpoints.**

7 (A) Selected significant ( $P < 1.40 \times 10^{-3}$ ) causal genetic links from clinical endpoints  
8 (Exposure) to liver imaging traits (Outcome) with adjustment for multiple testing using  
9 the FDR procedure. (B). Selected significant ( $P < 1.40 \times 10^{-4}$ ) causal genetic links from  
10 clinical endpoints (Exposure) to pancreas imaging traits (Outcome) with adjustment for  
11 multiple testing using the FDR procedure. (C). Selected significant ( $P < 1.40 \times 10^{-3}$ ) causal  
12 genetic links from clinical endpoints (Exposure) to spleen imaging traits (Outcome) with  
13 adjustment for multiple testing using the FDR procedure. (D). Selected significant ( $P <$   
14  $1.40 \times 10^{-4}$ ) causal genetic links from liver imaging traits (Exposure) to pancreas clinical  
15 endpoints (Outcome) with adjustment for multiple testing using the FDR procedure. The  
16 term 'IDP Category' is used to signify the category of imaging traits, while '#IVs' stands for  
17 the number of genetic variants utilized as instrumental variables. Various MR methods  
18 and their associated regression coefficients are marked with different colors for easy  
19 identification. (E). A high-level summary of our bidirectional findings. See **Table S1** for  
20 data resources on clinical endpoints and **Table S2** for data resources on imaging traits.

21

22 **Fig. 5 Selected genetic causal effects between skeleton imaging traits and clinical**  
23 **endpoints.**

24 We illustrated selected significant ( $P < 1.04 \times 10^{-4}$ ) causal genetic links from (A) skeleton  
25 imaging traits (Exposure) to clinical endpoints (Outcome) with adjustment for multiple  
26 testing using the FDR procedure and (B) clinical endpoints (Exposure) to skeleton imaging  
27 traits (Outcome). The term 'IDP Category' is used to signify the category of imaging traits,  
28 while '#IVs' stands for the number of genetic variants utilized as instrumental variables.  
29 Various MR methods and their associated regression coefficients are marked with  
30 different colors for easy identification. The skeleton diagram on the right shows the region

- 1 of the corresponding IDP. See **Table S1** for data resources on clinical endpoints and **Table**
- 2 **S2** for data resources on imaging traits.
- 3




Figure 1




Figure 2




Figure 3




Figure 4






Figure 5